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Cosme,2 Adalberto Benito,2 Teresa Gimenez,3 Jesus Merino,4 Ramón Merino,5 Manuel Arias1,2
Objectives: The contribution of humoral immune response in allograft and xenograft 
rejection has been clearly demonstrated in recent years. For this reason, inhibition of 
alloantibody production has become essential in managing transplanted patients. Here, 
we assessed the effects of the leflunomide derivative FK778 (FK778) in the control of 
antibody production resulting from semi-allogeneic cognate T-B–cell interactions. 
Materials and Methods: BALB/c mice were tolerized at birth with semiallogeneic spleen 
cells from (BALB/c × C57BL/6) F1 mice, with or without overexpression of human bcl-
2 transgene in B cells. These tolerized mice were treated with different dosages of 
FK778, either from birth, or from the third week of age, when autoantibody production 
was detected. The production of autoantibodies, used as markers of semiallogeneic 
cognate T-B–cell interactions, was evaluated at different time points during drug 
administration or after the interruption of treatment.
Results: FK778 treatment started at birth inhibited the production of semiallogeneic-
driven antibodies in a dose-dependent manner. In addition, FK778 also reduced the 
levels of preformed circulating autoantibodies in adult mice, although the dosage 
required was 4 times higher than that used in neonates. However, the levels of IgG 
antibodies in these tolerized mice increased after FK778 withdrawal, indicating that 
FK778 failed to induce tolerance to semiallogeneic host CD4+ Th2 and/or donor B cells.
Conclusions: Our results demonstrate the efficacy of FK778 in the control of antibody 
production resulting from semiallogeneic cognate T-B–cell interactions. 
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In addition to the well-known contribution of T lymphocytes in allograft or xenograft rejection, 
multiple evidence indicates that B-cell–producing, alloreactive antibodies are actively involved in 
the pathogenesis of both acute and chronic allograft rejection (1-2) and xenograft rejection (3-
4). The main antigenic targets of antibody-mediated rejection are major histocompatibility 
complex molecules (both class I and class II) (5) and the ABO group antigens (6). However, 
minor histocompatibility antigens or other autoantigens also can be targets of antibody-mediated 
rejection (7-9). Immunoadsortion by protein A has been considered as a tool to overcome 
hyperacute xenograft rejection by reducing circulating Ab (10). At present, the most common 
strategies for treatment of antibody-mediated rejection are based on the quick reduction of 
antibody titres using plasmapheresis in combination with aggressive immunosuppression (11). 
Although several immunosuppressor drugs (eg, mycophenolate mofetil or tacrolimus) can 
prevent antibody-mediated rejection (11), the discovery of new, immunosuppressive drugs that 
efficiently block alloantibody production in well-defined experimental models of allogeneic T-B–
cell interactions is of paramount importance to define novel, and more-efficient therapies against 
antibody-mediated rejection. 
FK778 (Astellas Pharma US, Inc., Deerfield, IL, USA), a synthetic malononitrilamide derived from 
the active metabolite of leflunomide (A77 1726), is an immunosuppressive drug that exerts its 
activity by inhibiting de novo pyrimidine synthesis by blocking the mitochondrial enzyme dihydro-
orotate de-hydrogenase, and possibly, inhibition of tyrosine kinase activity (12-15). FK778 
inhibits both T-cell and B-cell function (13, 16), and induces the generation of CD4+CD25+ 
regulatory T-cells in vitro (17).
In this study, we explore the efficacy of FK778 treatment in the prevention of antibody 
production resulting from an in vivo, cognate, semiallogeneic T-B–cell interaction. For this 
purpose, we used the experimental model of induction of neonatal tolerance to major 
histocompatibility complex alloantigens. In this model, the injection of semiallogeneic lymphoid 
cells differing in major histocompatibility complex class II molecules—but not in major 
histocompatibility complex class I or nonmajor histocompatibility complex alloantigens—into 
newborn parental mice induces immunologic tolerance to donor tissues, and the establishment of 
a donor B- and T-cell–chimerism (18, 19). However, host CD4+ Th2 cells recognizing I-A or I-E 
major histocompatibility complex class II alloantigens induce the polyclonal activation of donor B-
cells and the production of autoantibodies (autoAbs) (20, 21). An important feature of this model 
is that autoAbs production is self-limited, probably the consequence of a drop in donor B-cell 
chimerism (22). Indeed, the neonatal injection of semiallogeneic B-cells overexpressing a human 
bcl-2 transgene, promotes the maintenance of autoAbs production and the development of a 
lethal autoimmune syndrome (23). In this experimental model, using the production of IgG anti-
DNA antibodies as a marker of the establishment of allogeneic T-B–cell interactions, we analyze 
the effect of FK778 in inhibiting the generation of allogeneic-driven autoAbs. 
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Materials and Methods
Mice and neonatal induction of tolerance to alloantigens. 
BALB/c and C57BL/6 mice were acquired from Harlan Ibérica (Barcelona, Spain). C57BL/6-Ig-
human bcl-2 transgenic mice (C57BL/6-Ig-human bcl-2 transgenic mice), overexpressing hBcl-2 
in B cells (24), were generously provided by Dr Stanley J. Korsmeyer (Dana-Farber Cancer 
Institute, Harvard Medical School, Boston, MA, USA). (BALB/c × C57BL/6) F1 mice were obtained 
in our animal facilities. The presence of hBcl-2 in F1 mice was assessed in peripheral blood 
mononuclear cells by flow cytometry using a specific monoclonal antibody against hBcl-2 (clone 
6C8; Pharmingen, San Diego, CA, USA), as previously described (23). 
Neonatal tolerance to H-2b alloantigens was induced by an ip injection of 7 × 107 spleen cells 
from (BALB/c x C57BL/6) F1-hbcl-2 Tg mice or 108 spleen cells from (BALB/c × C57BL/6) F1 
mice into BALB/c mice within the first 24 hours of life, as described previously (23). These 
numbers of spleen cells were chosen to inject the same absolute number of B cells in both 
groups of mice, as determined by flow cytometry (23). Mice were bled from the retro-orbital 
plexus, and the resulting sera stored at -20°C until use. All studies were approved by the 
University of Cantabria Institutional Laboratory Animal Care and Use Committee.
Study protocol 
Group 1: To explore and titrate, in vivo, the efficacy of FK778 to prevent antibody production 
resulting from allogeneic T-B–cell interactions, BALB/c mice were injected with 108 spleen cells 
from  
(BALB/c × C57BL/6) F1 mice and were treated ip with 5 mg/kg (group 1a, n=25) or 20 mg/kg 
(group 1b, n=7) of FK778 (Astellas Pharma US, Inc., Deerfield, IL, USA), diluted in 0.1% 
carboxymethylcellulose, 3 times per week, from day 1 of life until the third week of age.
Group 2: To explore the efficacy of FK778 in inhibiting the production of preformed allogeneic-
driven antibodies, BALB/c mice injected at birth with 107 spleen cells from (BALB/c × C57BL/6) 
F1-hbcl-2-Tg mice, overexpressing hBcl-2 in B cells, were treated with FK778 ip 20 mg/kg (group 
2a, n=7) or 80 mg/kg (group 2b, n=10) 3 times per week, for 6 weeks, from the third to the 
ninth week of age, when treatment was stopped. 
Group 3 (n=16): In case of lack of effectiveness of the lower therapeutic regimen in group 2, we 
analyzed if this was related to the fact that the donor B cells used there overexpressed hBcl-2. 
With this aim, a group of mice were tolerized with 107 spleen cells from (BALB/c × C57BL/6) F1-
hbcl-2-Tg mice and received treatment with FK778 from birth up to the third week of age, with 
FK778 at a dose of 20 mg/kg. 
Group 4 (n=10): To study whether the FK778 treatment could promote the induction of 
tolerance to alloantigens in vivo; thus, preventing the activation of allogeneic donor B-cell after 
FK778 withdrawal, BALB/c mice neonatally tolerized with spleen cells from (BALB/c × C57BL/6) 
F1-hbcl-2-Tg mice were treated with 80 mg/Kg of FK778, 3 times a week, from the third week of 
age for 9 weeks, and then the treatment was stopped. After that, mice were followed 
serologically 3 weeks after the interruption of FK778 treatment.
Group 5: Tolerized controls. Group 5a (n=5): BALB/c mice injected with 108 spleen cells from 
(BALB/c × C57BL/6)F1 mice ip solvent treated 3 times per week as tolerized controls. Group 5b 
(n=6): BALB/c mice injected with 107 spleen cells from (BALB/c × C57BL/6)F1 hbcl-2-Tg mice ip 
solvent treated, 3 times per week, as tolerized controls. 
Group 6 (n=6): BALB/c mice were ip solvent treated, 3 times per week, as nontolerized controls.
Serologic assays 
Serum levels of total IgG and IgG anti-ssDNA autoAbs were determined by ELISA, as described 
elsewhere (23). Results were expressed in mg/mL in reference to a standard curve obtained with 
a mouse reference serum (ICN Biomedicals, Irvine, CA, USA), in the case of total IgG, or in 
titration units (U/mL) in reference to a standard curve obtained with a serum pool from a 6- to 8-
month-old MRL.lpr/lpr mice, for IgG anti-ssDNA autoAbs.
Statistical analyses 
Statistical analyses of differences between groups of mice were performed using the Wilcoxon 2-
sample test. Probability values < .05 were considered significant.
Results
1. FK778 completely inhibits the generation of de novo antibodies secondary to 
allogeneic T-B–cell interactions. 
In group 1b, FK778 at 20 mg/kg, totally inhibited the induction of IgG hypergammaglobulinemia 
and the production of IgG anti-ssDNA autoAbs in comparison to solvent treated tolerized controls 
(group 5a), which exhibited higher levels of circulating IgG (0.56 ± 0.04 mg/mL vs 5.29 ± 0.6 
mg/mL) and IgG anti-ssDNA (10.7 ± 0.6 U/mL vs 180.2 ± 8.2 U/mL) autoAbs (P < .003 in both 
 
Figure 1. Effect of FK778 treatment in 
the production of de novo antibodies 
secondary to allogeneic T-B–cell 
interactions. BALB/c mice were 
tolerized at birth with spleen cells 
from (BALB/c × C57BL/6) F1 mice and 
treated from day 1 up to the 
thirdweek of agewith either 5mg/kg 
(group 1a) or 20mg/kg (group 1b) of 
FK778 3 times per week. Nontolerized 
(group 6) and tolerized BALB/c mice-
treated with solvent (group 5a) were 
used as controls. Serum levels of total 
IgG (left) and IgG anti-ssDNA(right) 
after 3weeks of treatment are 
expressed in each individualmouse 
asmg/mL or U/mL, respectively
 
 
Figure 2. Effect of FK778 treatment in 
the production of preformed 
antibodies secondary to allogeneic T-
B–cell interactions. BALB/c mice were 
tolerized at birth with spleen cells 
from (BALB/c × C57BL/6)F1-hbcl-2-Tg 
mice. From the third week of age, 
tolerized mice were treated with either 
20 mg/kg (◊) (group 2a) or 80 mg/kg 
(∆) (group 2b) of FK778 3 times 
perweek.Nontolerized (O) (group 6) 
and tolerized BALB/cmice treatedwith 
solvent (×) (group 5b)were used as 
controls. Themean ± SD of 
serumlevels of total IgG (left) and IgG 
anti-ssDNA(right) are expressed at 
different time points inmg/mL or U/mL.
 
 
Figure 3. Effect of FK778 treatment in 
the induction of immunologic 
tolerance. BALB/c mice were tolerized 
at birth with spleen cells from (BALB/c 
× C57BL/6)F1-hbcl-2-Tgmice. 
Fromthe third week up to the 12th 
week of age, tolerized mice were 
treated with either 80 mg/Kg  of 
FK778, 3 times per week (group 4), or 
solvent  (group 5b). The mean ± 
SD of serum levels of total IgGand are 
expressed inmg/mLat different time 
points during and after FK778 
treatment.
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cases) (Figure 1). In group 1a, FK778 at 5 mg/kg reduced significantly the levels of total IgG and 
antibodies after 3 weeks of treatment in only 44% of tolerized mice (11 mice from a total of 25 
mice), compared to group 5a (4.82 ± 0.73 mg/mL vs 5.29 ± 0.64 mg/mL, P = NS) and IgG anti-
ssDNA (101.6 ± 15.1 U/mL vs 180.2 ± 8.2 U/mL, P = .02) (Figure 1). 
2. Higher dosages of FK778 are required to inhibit the production of preformed 
antibodies secondary to allogeneic T-B–cell interactions. 
Mice from group 2 injected at birth with 7 × 107 spleen cells from (BALB/c × C57BL/6)F1-hbcl-2-
Tg mice exhibited, at the third week of age, in relation to solvent treated tolerized mice (group 
5b), similar increased levels of circulating total IgG and IgG anti-ssDNA autoAbs (group 2a: 8.83 
± 0.27 mg/mL and 172.8 ± 17.7 U/mL; group 2b: 8.16 ± 0.72 mg/mL and 156.8 ± 18.7 U/mL; 
group 5b: 8.03 ± 0.27 mg/mL and 146.1 ± 16.5 U/mL) (P = NS in all cases) and, in relation to 
nontolerized controls (group 6), significantly increased levels of both circulating total IgG and  
IgG anti-ssDNA autoAbs (0.49 ± 0.02 mg/mL and 10.6 ± 0.7 U/mL) (P < .05) as expected 
(Figure 2). The initiation of FK778 treatment at this time point, at a dosage of 20 mg/kg 3 times 
per week (group 2a), the dosage used in neonatal mice to completely block de novo generation 
of autoAbs (Figure 1), was very inefficient in reducing serum levels of total IgG and IgG anti-
ssDNA, after 6 weeks of treatment (9 weeks of age) compared with tolerized controls (group 5b) 
(7.2 ± 1.1 mg/mL vs 9.1 ± 0.8 mg/mL) (P = NS) and (151.0 ± 29.5 U/mL vs 162.6 ± 13.7 U/
mL) (P = NS) (Figure 2). In fact, only 43% (3 of 7) of mice treated with 20 mg of FK778 from 
the third week of age showed a reduction in the titres of IgG anti-ssDNA (mean of 90.3 ± 32.9 U/
mL), but none had reduced levels of circulating total IgG.
Treatment from birth up to the third week of age with FK778 at the dosage of 20 mg/kg, 3 times 
per week, completely interfered with de novo production of IgG anti-ssDNA autoAbs in mice 
tolerized with spleen cells from (BALB/c × C57BL/6)F1-hbcl-2-Tg mice (group 3) compared to 
tolerized mice with (BALB/c × C57BL/6)F1-hbcl-2-Tg spleen cells (group 5b): 7.1 ± 0.3 U/mL 
(n=16) vs 118.1 ± 73.7 U/mL (n=6) (P = .0009) and was similar to IgG anti-ssDNA autoAbs in 
nontolerized BALB/c mice (group 6): 8.2 ± 0.6 U/mL (n=6) (P = NS). However, a 4-fold increase 
in the dosage of FK778 (80 mg/kg of FK778, 3 times per week), administered from the third 
week of age into autoAb positive mice tolerized with (BALB/c × C57BL/6)F1-hbcl-2-Tg spleen 
cells  
(group 2b), could significantly reduce (compared to group 5b) the preformed anti-ssDNA autoAbs 
(80.7 ± 11.9 vs 162.6 ± 13.7 U/mL) (P = .001) and hyper-gamma-globulinemia in 100% of 
animals (3.32 ± 0.59 vs 9.1 ± 0.8 mg/mL) (P = .0008) (Figure 2).
3. Treatment with FK778 fails to promote immunologic tolerance of semiallogeneic 
host CD4+ Th2 and/or donor B cells 
The interruption of FK778 treatment in group 4 was followed 3 weeks later by the appearance of 
IgG hypergammaglobulinemia at levels comparable to those observed in these animals before 
the treatment (group 5b) (10.2 ± 1.57 vs 17.19 ± 2.64 mg/mL) (P = NS) (Figure 3). Similarly, 
IgG hypergamma-globulinemia was observed 3 and 6 weeks after the interruption of drug 
administration in tolerized mice treated from birth up to the third week of age with 20 mg/kg of 
FK778 3 times per week (data not shown).
Discussion
The acceptance of allografts in animals or humans lacking T cells for a long time supports the 
misconception that these cells were the only, or at least, the major mediators, of allograft 
rejection. This idea largely underestimated the contribution of humoral immune responses in the 
pathogenesis of xeno and allograft rejection (1-4, 25-26). However, over the past few years, 
multiple evidence indicates that alloreactive antibodies play important roles in a significant 
proportion of both acute and chronic rejection episodes, particularly those involved in graft 
failure (1, 2, 25-27). For this reason, an adequate treatment to prevent xeno and allograft 
rejection should take in consideration not only the inhibition of T-cell alloresponses, but also the 
effective blockade of xeno and alloantibody production. 
In the present study, we have evaluated in a well-established model of semiallogeneic-driven CD4
+ T-cell–mediated polyclonal activation of B cells, the effectiveness of FK778 in the prevention of 
antibody production. Our results demonstrate that FK778 largely blocks both de novo and the 
preformed production of semiallogeneic-driven autoAbs. However, the dosages required for the 
effective inhibition of preformed antibodies are significantly higher than those used for the 
inhibition of de novo produced antibodies. In addition, we demonstrate here that the in vivo 
treatment with FK778 fails to promote CD4+ T- and B-cell tolerance.
We have used a previously well-documented model of semiallogeneic T-B–cell interaction 
secondary to the induction of neonatal tolerance to H-2 alloantigens (18-23). In this model, the 
injection of semiallogeneic (BALB/c × C57BL/6) F1 H-b/d spleen cells, either with or without 
overexpression of hBcl-2 in B cells, into BALB/c H-2d neonates, promotes the induction of 
tolerance of host CD4+ Th1 and CD8+ T cells, that is manifested by, among other findings, the 
persistence of donor B-cell chimerism. However, these donor B cells expressing the H-2b 
alloantigen are polyclonally activated by non-tolerized H-2b-specific BALB/c host CD4+ Th2 cells 
to produce a wide repertoire of IgG1 and IgE antibodies, including multiple autoAbs (20). Several 
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characteristics make this experimental model suitable to test under stringent conditions the 
efficacy of new immunosuppressive drugs in the control of alloantibody production; a) the nature 
of the alloantigen, the H-2b alloantigen, involved in this cognate T-B–cell interaction is well 
established (18, 19, 21), b) the number of precursors engaged in this interaction is even higher 
than in transplanted patients (especially if it is taken in consideration that all donor B cells may 
be activated in this model [28]), c) using different mouse donor sources (F1 mice with or without 
overexpression of hBcl-2 in B cells) (23), it allows analysis of the effect of the drug in situations 
where alloreactive host CD4+ T cells have not been previously exposed to the antigen (naive T 
cells), or when they have been activated, and memory T cells have been generated (see below), 
and d) autoAbs can be employed as serologic markers of this semiallogeneic interaction (28). 
FK778 completely inhibits the generation of de novo antibodies secondary to allogeneic T-B–cell 
interactions; however, the protective effect of FK778 on autoAbs production was dose-
dependent, because the dosage of 5 mg/kg of FK778, 3 times per week, was able to reduce only, 
either partially or totally, the levels of IgG anti-ssDNA and total IgG antibodies after 3 weeks of 
treatment in about 40% to 50% of tolerized mice (Figure 1), whereas 20 mg/kg of FK778, 3 
times per week, put an end to autoAbs production. 
An important finding of our study is that the dosage of FK778 required to reduce the levels of 
preformed allogeneic-driven autoAbs in tolerized adult mice treated from the third week of age is 
4 times higher than the dosage used to block de novo production of such antibodies in mice 
treated from birth. In this case, we used a previously reported modification of the model of 
neonatal tolerance to alloantigens described above, consisting of the use of (BALB/c × C57BL/6) 
F1-hbcl-2-Tg mice over-expressing hBcl-2 in B cells as the source of donor spleen cells injected 
at birth into BALB/c mice (23). In this model, and secondary to the enlarged survival of donor B 
cells that prolongs the persistence of donor B-cell chimerism, the increased levels of autoAbs are 
maintained chronically inducing a lethal autoimmune syndrome in these tolerized mice (23). 
This difference in the FK778 dosages required is unrelated to the source of spleen cells used to 
induce neonatal tolerance to alloantigens, either (BALB/c × C57BL/6)F1-hbcl-2-Tg or non-Tg F1 
mice. In fact, the treatment from birth with FK778 at a dosage of 20 mg/kg, 3 times per week, is 
equally effective preventing the production of autoAbs in BALB/c mice tolerized with spleen cells 
from each F1 donor. Two mutually nonexclusive possibilities may explain this difference. First, 
although the dosage of immunosuppressant has been precisely adapted in every injection to the 
weight of individual animals, we cannot exclude the possibility of variations in the metabolism 
and/or body distribution of the drug between very young (mice from birth up to the third week of 
age) and more adult (from the third week of age on) mice; in this sense, a measurement of 
plasma levels of the drug could add additional information. Alternatively, a possible explanation 
for the different FK778 dosages required to inhibit antibody production in our experimental 
groups may be related to the presence in mice treated from the third week of age with 
semiallogeneic memory CD4+ Th2 cells that are absent in neonatal mice. These memory CD4+ 
Th2 cells could be more refractory to FK778 inhibition than the newly generated, semiallogeneic 
host CD4+ Th2 cells in the neonates. The control of alloreactive memory T cells, which may be 
already present in nonpreviously, immunized, pre-transplanted patients, constitutes 1 of the 
major challenges for transplant immunotherapy (29, 30). In this regard, although successful 
attempts to control memory T-cell responses have been reported (31), human memory 
alloreactive CD4+ T-cells stimulated in vitro seem to be refractory to the suppressive effects of 
steroids, deoxyspergualin, and sirolimus do not to the calcineurin inhibitor tacrolimus, or, to a 
lesser extent, cyclosporine (32). 
It has been reported recently that in vitro FK778 induces the generation of regulatory T-cells 
from naive CD4+CD25- T-cells (17). Because regulatory T-cells are very efficient at controlling 
the activation of B cells (33), this mechanism may explain the absence, or the reduction, of 
autoAbs in the different groups of tolerized mice treated with FK778. However, the reinduction of 
autoAbs production in these treated mice shortly after the interruption of the treatment in our in 
vivo model strongly argues against this possibility. Whatever the mechanism’s involved in the 
split of tolerance observed in mice tolerized at birth with semiallogeneic spleen cells, we show 
here that FK778 is unable to promote tolerance in semiallogeneic host CD4+ Th2 and donor B 
cells without apparently affecting the induction of tolerance of host CD4+ Th1 and CD8+ cells, 
evidenced by the persistence of B-cell chimerism for several weeks after FK778 withdrawal. In 
view of these results, we favor the idea that FK788 directly interferes with the activation of CD4+ 
T and B cells. In fact, A77 1726, the active metabolite of leflunomide from which FK778 is 
derived, has been shown to interfere with the phosphorylation of several tyrosine kinases 
involved in T-cell activation, to block the proliferation of T cells induced by several mitogens, and 
to inhibit the proliferation and antibody production of B cells in vitro (14, 16). 
This study, however, has several limitations. One is that we cannot assure differences in 
metabolism and distribution of the drug in neonatal mice that could influence the response seen 
in our experiments. Secondly, unfortunately, during the development of the experiments, FK778 
was withdrawn from the immunosuppression therapeutic arsenal in June 2006 owing to results of 
phase II trials that indicated unclear benefits over current treatment options. However, current 
studies suggest a role for FK778 in the prevention of chronic allograft nephropathy in a rat 
transplant model (34, 35), as well as decreasing the susceptibility of xenograft to acute or 
chronic rejection (36).
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Together, our study indicates that FK778 is an efficient immunosuppressant for the control of 
antibody production resulting from allogeneic cognate T-B–cell interactions.
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